WTO Trains Officials On TRIPS Flexibilities For Public Health 18/10/2011 by Intellectual Property Watch 2 Comments The World Trade Organization today concluded a four-day training session to help officials from developing countries better understand the flexibilities to intellectual property rights built into international trade rules on IP.
Medicines Patent Pool Signs Deal With Indian Generics Producer 11/10/2011 by William New, Intellectual Property Watch 2 Comments The Medicines Patent Pool, which negotiates voluntary licences for lower pharmaceutical prices, today announced the signing of an agreement with generics producer Aurobindo Pharma Limited to manufacture antiretroviral medicines. The Patent Pool has recently come under criticism from AIDS activists concerned about its July licence agreement with drug company Gilead, and it remains to be seen if this action will address their concerns.
As Bilateral Trade Deals Proceed, WIPO Hears Warnings, Calls For Change 04/10/2011 by William New, Intellectual Property Watch 1 Comment As some developed countries prepared to ink a secret plurilateral trade agreement against rampant global piracy and counterfeiting in recent days, leading emerging economies and non-governmental groups warned the World Intellectual Property Organization that such outside agreements need to respect broader societal impacts of IP rights enforcement or risk abuses of international rules on trade and development.
Health Impact Fund – Raising Issues Of Distribution, IP Rights And Alliances 26/09/2011 by Intellectual Property Watch 1 Comment This piece raises several issues with the public health financing proposal called the Health Impact Fund. It questions the relative distribution of costs and benefits; the persistent issue of intellectual property rights; as well as a lack of alliance with existing efforts to increase innovation of and access to essential medicines for the poor.
Questions Arise Over UN Policy On Non-Communicable Diseases And IP Rights 16/09/2011 by William New, Intellectual Property Watch 2 Comments United Nations members this month are setting the future course for global action against a rising public health problem well-known in developed countries and spreading to developing countries: noncommunicable diseases. But whether they will – or should – address concerns that intellectual property rights issues might interfere with access to treatments for such diseases as diabetes, cancer, or heart disease remains to be seen.
NCDs Pose Major Threat to Public Health, WHO Reports 15/09/2011 by Intellectual Property Watch Leave a Comment The greatest threat to global public health is not infectious diseases according to the World Health Organization. In a report released this week, the WHO found that noncommunicable diseases (NCDs) are the top cause of death worldwide. The report details the NCD situation in 193 countries and comes as world leaders prepare to meet at the United Nations high-level meeting on NCDs in New York on 19-20 September.
South Africa Conference On IP And Innovation 14/09/2011 by Intellectual Property Watch 1 Comment A conference being held in South Africa this week will address the sensitive topic of intellectual property and innovation in the developing country context. On hand will be a top team of developed country experts with a mix of Indian and Chinese specialists.
“Washington Declaration” Demands Return Of Public Interest In IP Rights 10/09/2011 by William New, Intellectual Property Watch 5 Comments A new multi-stakeholder declaration demanding that the public interest be returned to intellectual property rights was issued this week and is open for signatures by anyone, already collecting hundreds of supporters. The declaration contains numerous principles and actions, such as restraint in enforcement, open access, and development priorities, that the drafters hope will help change the course of IP policymaking.
Corporate Self-Interest And Strategic Choices: Gilead Licenses To Medicines Patent Pool 21/07/2011 by Intellectual Property Watch 3 Comments Gilead’s recently announced ARV licenses to the Medicines Patent Pool, although positive in some respects, still unreasonably limit the geographical access of key middle-income countries and restrict the sourcing of APIs and products to Indian companies, meaning that both generics companies and excluded countries will need to make strategic decisions to bypass the defects in the licenses, writes Brook Baker.
Kenya Opens Region’s Door To GM Maize 19/07/2011 by Intellectual Property Watch Leave a Comment In the face of a severe food shortage, Kenya’s Cabinet has approved imports of genetically modified maize, though it has drawn the line on use of GM maize as seeds, a regional newspaper reports.